Skip to main content
Premium Trial:

Request an Annual Quote

NCI Launches Study for PGx-Based Breast Cancer Treatment; Oncotype Dx Plays Role

NEW YORK, May 24 (GenomeWeb News) - The National Cancer Institute yesterday said it has launched TAILORx, a pharmacogeomics-based trial for breast cancer treatment.


TAILORx, which stands for Trial Assigning IndividuaLized Options for Treatment, will examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate treatment.


TAILORx hopes to incorporate a molecular profiling test into clinical decision-making, sparing women from unnecessary treatments if chemotherapy would not be beneficial. The study will use Oncotype DX, a diagnostic developed by Genomic Health.


Sponsored by NCI and coordinated by the Eastern Cooperative Oncology Group, TAILORx will enroll over 10,000 women recently diagnosed with estrogen receptor or progesterone receptor positive, Her2/neu-negative breast cancer that has not yet spread to lymph nodes. The study will be conducted at 900 sites in the US and Canada.


The women will be studied for 10 years with an additional follow-up of up to 20 years after initial therapies. There will be three treatment groups: standard care (chemotherapy and hormonal therapy), hormonal therapy only, and adjuvant hormonal therapy with or without chemotherapy. Approximately 44 percent of the participants will be in the third group.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.